FDA clears DeFloria’s cannabis-based autism treatment for phase 2 trial
DeFloria’s cannabinoid drug advances through the regulatory pipeline as the company targets growing ASD market.
The post FDA clears DeFloria’s cannabis-based autism treatment for phase 2 trial appeared first on Green Market Report.
